{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:24:09Z","timestamp":1794007449100,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100013278","name":"EU Joint Programme\u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["AC21_2\/00017"],"award-info":[{"award-number":["AC21_2\/00017"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme\u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["AC21_2\/00017"],"award-info":[{"award-number":["AC21_2\/00017"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00611"],"award-info":[{"award-number":["PI22\/00611"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00327"],"award-info":[{"award-number":["PI21\/00327"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015496","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas","doi-asserted-by":"publisher","award":["Program 1, Alzheimer disease"],"award-info":[{"award-number":["Program 1, Alzheimer disease"]}],"id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["AGAUR 2019 PROD 00088"],"award-info":[{"award-number":["AGAUR 2019 PROD 00088"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01685-y","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:31:14Z","timestamp":1740375074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer\u2019s pathophysiological biomarkers"],"prefix":"10.1186","volume":"17","author":[{"given":"Alba Cervantes","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Vera","family":"Campuzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Bel\u00e9n","family":"S\u00e1nchez-Saudin\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Rodr\u00edguez-Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Lid\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danna","family":"Perlaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bejanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annakaisa","family":"Haapasalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeen","family":"Vanmechelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Belbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"1","key":"1685_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","volume":"3","author":"I McKeith","year":"2004","unstructured":"McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol. 2004;3(1):19\u201328.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1685_CR2","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O\u2019Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863\u201372.","journal-title":"Neurology"},{"issue":"2","key":"1685_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mds.26479","volume":"31","author":"L Calo","year":"2016","unstructured":"Calo L, Wegrzynowicz M, Santiva\u00f1ez-Perez J, Grazia Spillantini M. Synaptic failure and \u03b1-synuclein. Mov Disord. 2016;31(2):169\u201377.","journal-title":"Mov Disord"},{"issue":"12","key":"1685_CR4","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/NEN.0000000000000018","volume":"72","author":"M Colom-Cadena","year":"2013","unstructured":"Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Mart\u00ed MJ, et al. Confluence of \u03b1-synuclein, tau, and \u03b2-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2013;72(12):1203\u201312.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"1685_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","volume":"46","author":"M Sharma","year":"2023","unstructured":"Sharma M, Burr\u00e9 J. \u03b1-Synuclein in synaptic function and dysfunction. Trends Neurosci. 2023;46(2):153\u201366.","journal-title":"Trends Neurosci"},{"key":"1685_CR6","doi-asserted-by":"publisher","unstructured":"Goossens J, Cervantes Gonz\u00e1lez A, Dewit N, Lid\u00f3n L, Fortea J, Alcolea D et al. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2023;15(1):186. https:\/\/doi.org\/10.1186\/s13195-023-01336-0","DOI":"10.1186\/s13195-023-01336-0"},{"issue":"1","key":"1685_CR7","doi-asserted-by":"publisher","first-page":"E50","DOI":"10.1212\/WNL.0000000000207371","volume":"101","author":"L Barba","year":"2023","unstructured":"Barba L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, Paolini Paoletti F, Gaetani L, et al. CSF synaptic biomarkers in AT(N)-Based subgroups of Lewy Body Disease. Neurology. 2023;101(1):E50\u201362.","journal-title":"Neurology"},{"key":"1685_CR8","doi-asserted-by":"crossref","unstructured":"Alcolea D, Clarim\u00f3n J, Carmona-Iragui M, Ill\u00e1n-Gala I, Morenas-Rodr\u00edguez E, Barroeta I, et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Volume 5. Alzheimer\u2019s Dement. 2019;597\u2013609. (New York, N Y).","DOI":"10.1016\/j.trci.2019.09.005"},{"issue":"9","key":"1685_CR9","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Pegueroles J, Mu\u00f1oz L, Camacho V, L\u00f3pez-Mora D, Fern\u00e1ndez-Le\u00f3n A, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann Clin Transl Neurol. 2019;6(9):1815\u201324.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"1685_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1685_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1685_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, DIckson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"17","key":"1685_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743\u201355.","journal-title":"Neurology"},{"key":"1685_CR14","doi-asserted-by":"crossref","unstructured":"Galasko D, Xiao M, Xu D, Smirnov D, Salmon DP, Dewit N, et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer\u2019s disease. Volume 5. Alzheimer\u2019s Dement; 2019;871\u201382. (New York, N Y).","DOI":"10.1016\/j.trci.2019.11.002"},{"issue":"3","key":"1685_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1212\/WNL.49.3.786","volume":"49","author":"CR Jack","year":"1997","unstructured":"Jack CR, Petersen RC, Xu YC, Waring SC, O\u2019Brien PC, Tangalos EG, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer\u2019s Disease. Neurology. 1997;49(3):786.","journal-title":"Neurology"},{"key":"1685_CR16","doi-asserted-by":"crossref","unstructured":"Mccormack A, Keating DJ, Chegeni N, Colella A, Wang JJ, Chataway T. Abundance of synaptic vesicle-related proteins in Alpha-Synuclein-Containing Protein Inclusions Suggests a Targeted Formation Mechanism. Neurotox Res. 2019;35(4):883\u2013897.","DOI":"10.1007\/s12640-019-00014-0"},{"issue":"10","key":"1685_CR17","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1073\/pnas.1218424110","volume":"110","author":"BK Choi","year":"2013","unstructured":"Choi BK, Choi MG, Kim JY, Yang Y, Lai Y, Kweon DH, et al. Large \u03b1-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci U S A. 2013;110(10):4087\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1685_CR18","doi-asserted-by":"publisher","unstructured":"Brolin E, Ingelsson M, Bergstr\u00f6m J, Erlandsson A. Altered distribution of SNARE proteins in primary neurons exposed to different Alpha-Synuclein Proteoforms. Cell Mol Neurobiol. 2023;43(6);3023\u20133035. https:\/\/doi.org\/10.1007\/s10571-023-01355-3","DOI":"10.1007\/s10571-023-01355-3"},{"key":"1685_CR19","doi-asserted-by":"crossref","unstructured":"Shantaraman A, Dammer EB, Ugochukwu O, Duong DM, Yin L, Carter EK et al. Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer\u2019s disease. Mol Neurodegener. 2024;19(1).","DOI":"10.1186\/s13024-024-00749-1"},{"issue":"3","key":"1685_CR20","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1074\/mcp.RA118.001290","volume":"18","author":"A Lle\u00f3","year":"2019","unstructured":"Lle\u00f3 A, N\u00fa\u00f1ez-Llaves R, Alcolea D, Chiva C, Balateu-Pa\u00f1os D, Colom-Cadena M, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer\u2019s disease cerebrospinal fluid*. Mol Cell Proteom. 2019;18(3):546\u201360.","journal-title":"Mol Cell Proteom"},{"issue":"1","key":"1685_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JAD-200065","volume":"77","author":"N Sharda","year":"2020","unstructured":"Sharda N, Pengo T, Wang Z, Kandimalla KK, Arancio O. Amyloid-\u03b2 peptides disrupt interactions between VAMP-2 and SNAP-25 in neuronal cells as determined by FRET\/FLIM. J Alzheimers Dis. 2020;77(1):423\u201335.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"1685_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/jnnp-2021-328646","volume":"93","author":"S Halbgebauer","year":"2022","unstructured":"Halbgebauer S, Steinacker P, Hengge S, Oeckl P, Abu Rumeileh S, Anderl-Straub S, et al. CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2022;93(10):1059\u201365.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1685_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16(1):55.","journal-title":"Lancet Neurol"},{"key":"1685_CR24","doi-asserted-by":"crossref","unstructured":"Barba L, Abu-Rumeileh S, Barthel H, Massa F, Foschi M, Bellomo G et al. Clinical and diagnostic implications of Alzheimer\u2019s disease copathology in Lewy body disease. Brain. 2024;147(10).","DOI":"10.1093\/brain\/awae203"},{"issue":"21","key":"1685_CR25","doi-asserted-by":"publisher","first-page":"E2065","DOI":"10.1212\/WNL.0000000000012853","volume":"97","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, et al. CSF synaptic biomarkers in the preclinical stage of Alzheimer Disease and their Association with MRI and PET A cross-sectional study. Neurology. 2021;97(21):E2065\u201378.","journal-title":"Neurology"},{"issue":"1","key":"1685_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-008-0406-y","volume":"116","author":"KA Jellinger","year":"2008","unstructured":"Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol. 2008;116(1):1\u201316.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1685_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","volume":"78","author":"NSM Schoonenboom","year":"2012","unstructured":"Schoonenboom NSM, Reesink FE, Verwey NA, Kester MI, Teunissen CE, Van De Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78(1):47\u201354.","journal-title":"Neurology"},{"key":"1685_CR28","doi-asserted-by":"publisher","unstructured":"Agliardi C, Meloni M, Guerini FR, Zanzottera M, Bolognesi E, Baglio F et al. Oligomeric \u03b1-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson\u2019s disease. Neurobiol Dis. 2021;148;105185. https:\/\/doi.org\/10.1016\/j.nbd.2020.105185","DOI":"10.1016\/j.nbd.2020.105185"},{"key":"1685_CR29","doi-asserted-by":"publisher","unstructured":"Bereczki E, Bogstedt A, H\u00f6glund K, Tsitsi P, Brodin L, Ballard C et al. Synaptic proteins in CSF relate to Parkinson\u2019s disease stage markers. NPJ Park Dis. 2017;3:7. https:\/\/doi.org\/10.1038\/s41531-017-0008-2","DOI":"10.1038\/s41531-017-0008-2"},{"key":"1685_CR30","doi-asserted-by":"publisher","unstructured":"Van Steenoven I, Koel-Simmelink MJA, Vergouw LJM, Tijms BM, Piersma SR, Pham TV et al. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Mol Neurodegener. 2020;15(1):36. https:\/\/doi.org\/10.1186\/s13024-020-00388-2","DOI":"10.1186\/s13024-020-00388-2"},{"issue":"1","key":"1685_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10010038","volume":"10","author":"WA Boiten","year":"2020","unstructured":"Boiten WA, van Steenoven I, Xiao M, Worley PF, Noli B, Cocco C, et al. Pathologically decreased CSF levels of synaptic marker NPTX2 in DLB are correlated with levels of alpha-synuclein and VGF. Cells. 2020;10(1):1\u201313.","journal-title":"Cells"},{"key":"1685_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.parkreldis.2019.05.014","volume":"65","author":"R El-Nazer","year":"2019","unstructured":"El-Nazer R, Adler CH, Beach TG, Belden CM, Artz J, Shill HA, et al. Regional Neuropathology distribution and verbal fluency impairments in Parkinson\u2019s Disease. Parkinsonism Relat Disord. 2019;65:73.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1685_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0891988718774432","volume":"31","author":"D Duro","year":"2018","unstructured":"Duro D, T\u00e1buas-Pereira M, Freitas S, Santiago B, Botelho MA, Santana I. Validity and clinical utility of different clock drawing test Scoring systems in multiple forms of Dementia. J Geriatr Psychiatry Neurol. 2018;31(3):114\u201322.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"5","key":"1685_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1037\/0894-4105.22.5.553","volume":"22","author":"D Tranel","year":"2008","unstructured":"Tranel D, Rudrauf D, Vianna EPM, Damasio H. Does the clock drawing test have focal neuroanatomical correlates? Neuropsychology. 2008;22(5):553\u201362.","journal-title":"Neuropsychology"},{"issue":"14","key":"1685_CR35","doi-asserted-by":"publisher","first-page":"E1844","DOI":"10.1212\/WNL.0000000000011697","volume":"96","author":"DM Rentz","year":"2021","unstructured":"Rentz DM, Papp KV, Mayblyum DV, Sanchez JS, Klein H, Souillard-Mandar W, et al. Association of Digital Clock drawing with PET amyloid and Tau Pathology in normal older adults. Neurology. 2021;96(14):E1844\u201354.","journal-title":"Neurology"},{"issue":"5\u20136","key":"1685_CR36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000490045","volume":"45","author":"LJM Vergouw","year":"2018","unstructured":"Vergouw LJM, Salom\u00e9 M, Kerklaan AG, Kies C, Roks G, Van Den Berg E, et al. The Pentagon copying test and the clock drawing test as prognostic markers in dementia with Lewy Bodies. Dement Geriatr Cogn Disord. 2018;45(5\u20136):308\u201317.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1685_CR37","doi-asserted-by":"crossref","unstructured":"Van Steenoven I, Noli B, Cocco C, Ferri GL, Oeckl P, Otto M et al. VGF peptides in cerebrospinal fluid of patients with dementia with lewy bodies. Int J Mol Sci. 2019;20(19).","DOI":"10.3390\/ijms20194674"},{"issue":"3","key":"1685_CR38","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1021\/acs.jproteome.9b00824","volume":"19","author":"P Oeckl","year":"2020","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, Von Arnim CAF, Diehl-Schmid J, Froelich L, et al. Targeted Mass Spectrometry suggests Beta-synuclein as synaptic blood marker in Alzheimer\u2019s Disease. J Proteome Res. 2020;19(3):1310\u20138.","journal-title":"J Proteome Res"},{"issue":"9","key":"1685_CR39","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington H, Paterson RW, Portelius E, T\u00f6rnqvist U, Magdalinou N, Fox NC, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829\u201335.","journal-title":"Neurology"},{"issue":"1","key":"1685_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Hertze J, Zetterberg H, Landqvist Wald\u00f6 M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2016;3(1):12\u201320.","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"1685_CR41","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/prca.201500150","volume":"10","author":"J Remnest\u00e5l","year":"2016","unstructured":"Remnest\u00e5l J, Just D, Mitsios N, Fredolini C, Mulder J, Schwenk JM, et al. CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer\u2019s disease. Proteom - Clin Appl. 2016;10(12):1242\u201353.","journal-title":"Proteom - Clin Appl"},{"issue":"3","key":"1685_CR42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, H\u00f6glund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136(3):363\u201376.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1685_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/mds.27950","volume":"35","author":"S Hall","year":"2020","unstructured":"Hall S, Janelidze S, Zetterberg H, Brix B, Mattsson N, Surova Y, et al. Cerebrospinal fluid levels of neurogranin in parkinsonian disorders. Mov Disord. 2020;35(3):513\u20138.","journal-title":"Mov Disord"},{"issue":"2","key":"1685_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1192\/bjp.170.2.156","volume":"170","author":"Z Walker","year":"1997","unstructured":"Walker Z, Allen RL, Shergill S, Katona CLE. Neuropsychological performance in Lewy body dementia and Alzheimer\u2019s disease. Br J Psychiatry. 1997;170(2):156\u20138.","journal-title":"Br J Psychiatry"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01685-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:31:21Z","timestamp":1740375081000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01685-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01685-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the IRB (Institut de Recerca de l\u2019Hospital de la Santa Creu i Sant Pau\u2013 IIB Sant Pau) and was conducted in accordance with the Declarations of Helsinki. All participants gave their written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"E.V. is co-founder of ADx NeuroSciences NV, Zwijnaarde (Ghent), Belgium, J. G. is employee at ADx NeuroSciences NV. J.F. has served as a consultant for Novartis and Lundbeck, has received honoraria for lectures from Roche, NovoNordisk, Esteve and Biogen and served at advisory boards for AC Immune, Zambon and Lundbeck. D.A. participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac\u00e9utica S.L., Zambon S.A.U., Lilly and Esteve Pharmaceuticals. A.L. participated in advisory boards from Biogen, Eisai, Fujirebio-Europe, Novartis, NovoNordisk, Nutricia, Otsuka Pharmaceutical, and Zamb\u00f3n, and received speaker honoraria from Lilly, Biogen, KRKA and Zambon. D.A, J.F., A.L. and O.B. declare a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease) related to biomarkers included in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}